0001104659-23-032986.txt : 20230316 0001104659-23-032986.hdr.sgml : 20230316 20230316060146 ACCESSION NUMBER: 0001104659-23-032986 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230310 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 23737011 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm239718d1_8k.htm FORM 8-K
0001819576 false 0001819576 2023-03-10 2023-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 10, 2023

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 1.01 Entry Into a Material Definitive Agreement.

 

On March 10, 2023, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Fourth Amendment to Promotion Agreement (the “Fourth Amendment”) with Sandoz Inc. (“Sandoz”). The Fourth Amendment amended that certain Promotion Agreement (the “Promotion Agreement”), dated as of August 1, 2018, by and between Liquidia PAH and Sandoz, as amended by that certain First Amendment to Promotion Agreement, dated as of May 8, 2020, that certain Second Amendment to Promotion Agreement, dated as of September 4, 2020 and further amended by that certain Third Amendment to Promotion Agreement, dated as of November 18, 2022.

 

The Fourth Amendment provides for, among other things, (i) an agreement between Sandoz and Liquidia PAH to enter into an agreement with a third party for the repair and servicing of CADD-MS 3 pumps (the “New Agreement”), (ii) an agreement to split all payments due under the New Agreement evenly between Liquidia PAH and Sandoz, and (iii) to clarify certain terms and conditions related to the profit sharing between Sandoz and Liquidia PAH under the Promotion Agreement.

 

The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the complete terms and conditions of the Pump Development Agreement to be filed as an exhibit to the Company’s next Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission (the “SEC”).

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 16, 2023, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the full year ended December 31, 2022, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated March 16, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

March 16, 2023 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm239718d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update

 

-Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024

-Fortified financial position through 2024

-Company to host webcast today at 8:30 a.m. ET

 

MORRISVILLE, N.C., March 16, 2023 - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the full year ended December 31, 2022. The Company will host a webcast at 8:30 a.m. ET to discuss the 2022 financial results and provide a corporate update.

 

Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We made notable strides toward unlocking the full potential of Liquidia in 2022. Our legal and patent wins were major achievements, clarifying the path to legal resolution. If approved, YUTREPIA will provide patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD) with the option to receive a differentiated inhaled treprostinil product via a low-resistance dry powder inhaler. The ongoing open-label extension study continues to demonstrate the merits of YUTREPIA’s dosing flexibility and durability by attaining dosing levels that have not been achievable historically with Tyvaso®, thus enhancing the clinical ability to manage patients over time. Our revenue interest financing with HealthCare Royalty, one of the marquee royalty firms, provided significant non-dilutive capital to advance our platform goals. As an example, our recently announced partnership with Mainbridge Health Partners will advance a new subcutaneous infusion pump for Treprostinil Injection, a therapeutically equivalent and less expensive generic option. We look forward to continuing to unlock value in 2023.”

 

Corporate Updates

 

New leadership to prepare for commercialization. During the year, the Company hired key employees in the C-suite, in the sales force and in operational units to support the potential launch of YUTREPIA. The net impact added decades of combined experience in the development and commercialization of medicines to treat pulmonary hypertension between Chief Executive Officer Dr. Roger Jeffs, Chief Medical Officer Dr. Rajeev Saggar, Head of Sales Matt Snow, and Head of Medical Affairs Gareth Gwyn. Additionally, the Company established key commercial support functions to address all stakeholders and bolstered manufacturing teams to build commercial inventory in preparation for YUTREPIA’s potential final approval by the U.S. Food and Drug Administration (FDA).

 

Clarified path to legal resolution with key wins. The Company demonstrated in at least one legal forum that all of the claims in three patents asserted by United Therapeutics Corporation (UTC) are invalid or not infringed. If every decision in favor of Liquidia is affirmed on appeal by UTC, then Liquidia would be clear to seek final regulatory approval of YUTREPIA. The Company expects legal resolution in late 2023 or the first half of 2024.

 

 

 

As background, in 2020, UTC filed litigation in the United States District Court for the District of Delaware (District Court) under the Drug Price Competition and Patent Term Restoration Act (the Hatch-Waxman Litigation) alleging that Liquidia infringes U.S. Patent No. 9,593,066 (‘066 Patent), U.S. Patent No. 10,716,793 (‘793 Patent) and U.S. Patent No. 9,604,901 (‘901 Patent). In parallel inter partes review (IPR) proceedings before the Patent Trial and Appeal Board (PTAB), the Company sought to invalidate the claims of the three asserted patents.

 

Briefing in appeal of Hatch-Waxman Litigation now complete. In August 2022, the District Court ruled in Liquidia’s favor with respect to the ‘066 Patent, finding that five of the six asserted claims of the '066 Patent are invalid and that the remaining asserted claim is not infringed by Liquidia. At the same time, the District Court found that all of the claims of the ‘793 Patent were valid and infringed by Liquidia based on the arguments that were presented by Liquidia in the Hatch-Waxman Litigation. Liquidia appealed the District Court’s decision with respect to the ‘793 Patent to the U.S. Court of Appeals for the Federal Circuit (Federal Circuit), and UTC appealed the District Court’s decision with respect to the ‘066 Patent to the Federal Circuit. Briefing is now complete and the parties are awaiting a scheduled date for oral argument, which Liquidia expects to occur during the second or third quarter of 2023.

 

‘793 Patent deemed by PTAB to be invalid. In July 2022, the PTAB found in favor of Liquidia in the ‘793 IPR stating that all the claims of the ‘793 Patent have been shown to be unpatentable based on the preponderance of the evidence. In February 2023, the PTAB denied UTC ‘s request for a rehearing and, in so doing, reaffirmed and clarified its earlier decision that the claims of the ‘793 Patent are unpatentable. Based on earlier statements, UTC is expected to file an appeal of the PTAB decision to the Federal Circuit. Should the Federal Circuit affirm the PTAB’s decision, the PTAB’s decision would override any finding in the Hatch-Waxman Litigation that Liquidia has breached any valid claims of the ‘793 Patent.

 

‘901 Patent deemed by PTAB to be invalid and then withdrawn by UTC from litigation. In December 2021, UTC stipulated that, based on the District Court’s construction of the claims in the ‘901 Patent, Liquidia does not infringe any of the asserted claims of that patent. UTC has not appealed any issues related to the ‘901 Patent, which has now been dropped from the Hatch-Waxman Litigation.

 

Increased long-term commitment to Treprostinil Injection market. To improve patients’ access to subcutaneous infusion of treprostinil, the Company committed to alleviate the single-source dependence on the existing CADD-MS 3 system for subcutaneous delivery of Treprostinil Injection. In December, Liquidia, Sandoz and Mainbridge Health Partners established a collaboration to repurpose an FDA-approved infusion pump used for insulin with the objective of submitting a 510(k) in 2023. More recently, Liquidia and Sandoz have agreed to cooperate in taking actions designed to maintain the current inventory of CADD-MS3 pumps held at specialty pharmacies supporting PAH patients. Lastly, when establishing these new collaborations, Sandoz and Liquidia extended the term of the promotion agreement for Treprostinil Injection until December 31, 2032.

 

 

 

Fortified financial position through 2024. Liquidia continued to exercise financial discipline by focusing expenses and improving access to cash resources through a combination of a loan refinancing in January 2022, an underwritten public offering of equity in April 2022 and a revenue interest financing with HealthCare Royalty (HCRx) in January 2023 under which HCRx has agreed to pay us an aggregate of up to $100 million upon certain events. To date, HCRx has funded $32.5 million, of which $22.4 million was used to satisfy in full and retire our then existing debt obligations to Silicon Valley Bank (SVB), with the excess proceeds less transaction costs of approximately $0.7 million funded to the Company. When combined with the revenue generated by sales of Treprostinil Injection, the Company is well-positioned to launch YUTREPIA within the expected time frame for legal resolution. As for the Company’s exposure to Silicon Valley Bank (SVB), 99% of funds were invested in a Blackrock mutual fund, and therefore, should not have been exposed by the events of the last week. As of March 14, 2023, substantially all cash and cash equivalents have been transferred out of SVB to an account held with an accredited financial institution.

 

Full Year 2022 Financial Results

 

Cash and cash equivalents totaled $93.3 million as of December 31, 2022.

 

Revenue was $15.9 million for the year ended December 31, 2022, compared with $12.9 million for the year ended December 31, 2021. During the year ended December 31, 2022, the profit split percentage we received under our Promotion Agreement with Sandoz Inc. was 50%, whereas during the year ended December 31, 2021, the profit split percentage decreased from 80% to 50% as a result of achievement of predetermined cumulative sales thresholds. This decrease in profit split percentage was offset by an increase in the number of units sold. Revenue in 2022 is net of $2.7 million in amortization of the contract acquisition costs associated with the Promotion Agreement.

 

Cost of revenue was $2.9 million for the year ended December 31, 2022, compared with $3.0 million for the year ended December 31, 2021. Cost of revenue related to the Promotion Agreement as noted above and included (i) the cost of employing a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH, as well as key stakeholders involved in the distribution and reimbursement of Treprostinil Injection and (ii) amortization of the intangible asset associated with the Promotion Agreement.

 

Research and development expenses were $19.4. million for the year ended December 31, 2022, compared with $20.5 million for the year ended December 31, 2021. The decrease of $1.1 million or 5% was primarily due to a $0.9 million decrease in personnel, consulting, and stock-based compensation expenses. During the year ended December 31, 2022, we incurred $7.0 million related to our YUTREPIA program compared to a total of $6.7 million during the year ended December 31, 2021.

 

 

 

General and administrative expenses were $32.4 million for the year ended December 31, 2022, compared with $23.1 million for the year ended December 31, 2021. The increase of $9.3 million or 40% was primarily due to a $4.2 million increase in commercial, marketing, and personnel expenses in preparation for the potential commercialization of YUTREPIA and a $3.1 million increase in stock-based compensation expense driven by an option modification charge recorded in the first quarter of 2022.

 

Other expenses, net were $2.2 million for the year ended December 31, 2022, compared with $0.8 million for the year ended December 31, 2021. The increase of $1.4 million was primarily due to a $1.0 million loss on extinguishment of debt related to the refinance of our long-term debt during January 2022 and a $1.6 million increase in interest expense due to a higher debt balance and higher interest rate on our debt from the A&R SVB LSA, offset by a $1.1 million increase in interest income from higher cash and cash equivalents balances.

 

Net loss for during the year ended December 31, 2022, was $41.0 million, or $0.67 per basic and diluted share, compared to a net loss of $34.6 million, or $0.70 per basic and diluted share, for the year ended December 31, 2021.

 

About YUTREPIA™(treprostinil) inhalation powder

 

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. The FDA has confirmed that YUTREPIA may add the indication to treat pulmonary hypertension with interstitial lung disease (PH-ILD) without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for optimal deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

Tyvaso® is a registered trademark of United Therapeutics Corporation.

 

About Treprostinil Injection

 

Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA.

 

 

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to appeals arising from our patent litigation in the U.S. District Court for the District of Delaware or inter partes review proceedings conducted at the PTAB, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The favorable decisions of the PTAB in the IPRs for the ’793 and ‘901 patents and of the District Court in the Hatch-Waxman Litigation are not determinative of the outcome of any appeal of those decisions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) pandemic on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

Contact Information

 

Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 

 

 

Liquidia Corporation

Select Balance Sheet Data

 

   December 31,   December 31, 
   2022   2021 
Cash and cash equivalents  $93,283   $57,494 
Total assets  $129,198   $93,729 
Total liabilities  $38,776    28,464 
Accumulated deficit  $(350,596)   (309,581)
Total stockholders’ equity  $90,422    65,265 

 

Liquidia Corporation

Consolidated Statements of Operations and Comprehensive Loss

 

   Year Ended December 31, 
   2022   2021 
Revenue  $15,935   $12,853 
Costs and expenses:          
Cost of revenue   2,859    3,023 
Research and development   19,435    20,517 
General and administrative   32,411    23,110 
Total costs and expenses   54,705    46,650 
Loss from operations   (38,770)   (33,797)
Other income (expense):          
Interest income   1,090    33 
Interest expense   (2,338)   (762)
Loss on extinguishment of debt   (997)   (53)
Total other income (expense), net   (2,245)  $(782)
Net loss and comprehensive loss  $(41,015)  $(34,579)
Net loss per common share, basic and diluted  $(0.67)   (0.70)
Weighted average common shares outstanding, basic and diluted   60,958,862    49,677,737 

 

 

 

 EX-101.SCH 3 lqda-20230310.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20230310_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20230310_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm239718d1_ex99-1img001.jpg GRAPHIC begin 644 tm239718d1_ex99-1img001.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 10, 2023
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm239718d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2023-03-10 2023-03-10 iso4217:USD shares iso4217:USD shares 0001819576 false 8-K 2023-03-10 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm239718d1_8k.htm lqda-20230310.xsd lqda-20230310_lab.xml lqda-20230310_pre.xml tm239718d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm239718d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm239718d1_8k.htm" ] }, "labelLink": { "local": [ "lqda-20230310_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20230310_pre.xml" ] }, "schema": { "local": [ "lqda-20230310.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lqda", "nsuri": "http://liquidia.com/20230310", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239718d1_8k.htm", "contextRef": "From2023-03-10to2023-03-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://liquidia.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm239718d1_8k.htm", "contextRef": "From2023-03-10to2023-03-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-032986-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-032986-xbrl.zip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